Sino-Therapeutics Pharmaceutical released its 2026 interim report. During the reporting period, the company's total operating revenue was 191 million yuan, down 12.95% year-on-year. Net profit attributable to the parent company was 29.7 million yuan, down 34.84% year-on-year. Net cash inflow from operating activities was 85.05 million yuan, up 73.64% year-on-year. The company's asset-liability ratio was 10.59%, gross margin was 41.53%, return on equity was 2.25%, and diluted earnings per share was 0.07 yuan. The number of shareholders was 7,693, and the shareholding ratio of the top ten shareholders was 74.76%.
Sinotherapeutics Inc. ANet profit down 34.84% year-on-year in interim report.
